GE HealthCare Technologies Inc.'s stock surged 5.18% during intraday trading on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.

The medical device maker reported quarterly revenue of $5.70 billion, beating analyst estimates of $5.61 billion and representing a 7.1% year-over-year increase. Adjusted earnings per share came in at $1.44, surpassing the consensus estimate of $1.40. The company attributed this performance to robust demand for its diagnostic and imaging devices, driven by resilient demand for medical procedures, particularly from older Americans, and strength in U.S. and European markets.

Furthermore, GE HealthCare provided an optimistic outlook for 2026, forecasting adjusted earnings per share in the range of $4.95 to $5.15, above analysts' expectations of $4.92. The company also expects organic revenue growth of 3% to 4% year-over-year. Additionally, management indicated that the anticipated tariff impact for 2026 is expected to be lower than in 2025 based on current rates, providing further positive sentiment for investors.